Try our Advanced Search for more refined results

November 06, 2018

Wang v. Endocyte Inc et al

Track this case

Case Number:

4:18-cv-00085

Court:

Indiana Northern

Nature of Suit:

Securities/Commodities

Judge:

Joseph S Van Bokkelen

Companies

Sectors & Industries:

View recent docket activity

Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.

Coverage

  1. November 06, 2018

    Endocyte's $2.1B Sale To Novartis 'Unfair' To Investors: Suit

    Cancer treatment company Endocyte Inc. and its directors omitted crucial information from a proxy statement and undervalued the business in its $2.1 billion acquisition by Novartis AG, according to an investor who called the deal "fundamentally unfair" to stockholders in a lawsuit in Indiana federal court Tuesday.

Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

View the parties now

Already a subscriber? Click here to login